Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 149 No. 3940 (2019)

Drug prescription patterns, polypharmacy and potentially inappropriate medication in Swiss nursing homes: a descriptive analysis based on claims data

  • Rahel Schneider
  • Daphne Reinau
  • Nadine Schur
  • Eva Blozik
  • Mathias Früh
  • Andri Signorell
  • Christoph R. Meier
  • Matthias Schwenkglenks
DOI
https://doi.org/10.4414/smw.2019.20126
Cite this as:
Swiss Med Wkly. 2019;149:w20126
Published
30.09.2019

Summary

BACKGROUND

To date, comprehensive data on drug utilisation in Swiss nursing homes are lacking.

OBJECTIVE

To describe drug prescription patterns, polypharmacy and potentially inappropriate medication (PIM) in Swiss nursing home residents (NHR).

METHODS

Using administrative claims data provided by the Swiss health insurance company Helsana, we assessed drug claims and drug costs in 2016 in individuals aged ≥65 years and insured with Helsana, who were either NHR or living in the community (reference group, RG). In particular, we analysed the prevalence of polypharmacy (≥5 claims for different drugs during a 3-month period) and PIM use according to the 2015 Beers criteria and the PRISCUS list. We standardised the results to the Swiss population.

RESULTS

In 2016, NHR had on average nearly twice as many drug claims per capita as individuals in the RG (NHR 58.8; RG 30.8). The average per capita drug costs per day for NHR were low, but higher than in the RG (NHR CHF 8.55; RG CHF 5.45). The same pattern applied to the prevalence of polypharmacy (NHR 85.5%; RG 50.4%). Standardisation by age and sex did not materially alter these observations. Overall, 79.1% of NHR received ≥1 PIM, and 56.2% were long-term users (≥3 claims) of at least one PIM (based on the combined PRISCUS list and Beers criteria). Among all PIMs in nursing homes, quetiapine (antipsychotic agent), lorazepam (anxiolytic agent) and zolpidem (hypnotic agent) were the most prevalent (22.4, 20.2 and 13.0%, respectively).

CONCLUSIONS

The high prevalence of polypharmacy and PIM in Swiss nursing homes may indicate a need for interventions aiming at de-prescribing drugs with an unfavourable benefit-risk profile.

References

  1. OECD. Recipients of long-term care. Health at a Glance 2017: OECD Indicators. OECD Publishing. 2017. pp. 206. Available at: https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2017_health_glance-2017-en. Last accessed on 09 Oct. 2018.
  2. Bundesamt für Statistik. Taschenstatistik der Schweiz 2018. Bevölkerung. Bundesamt für Statistik, Sektion Diffusion und Amtspublikationen. 2018. pp. 5. Available at: https://www.bfs.admin.ch/bfs/de/home/statistiken/kataloge-datenbanken/publikationen.assetdetail.4522206.html. Last accessed on 11 Oct. 2018.
  3. Jokanovic N, Tan EC, Dooley MJ, Kirkpatrick CM, Bell JS. Prevalence and factors associated with polypharmacy in long-term care facilities: a systematic review. J Am Med Dir Assoc. 2015;16(6):535.e1–12. doi:.https://doi.org/10.1016/j.jamda.2015.03.003
  4. Moore KL, Boscardin WJ, Steinman MA, Schwartz JB. Patterns of chronic co-morbid medical conditions in older residents of U.S. nursing homes: differences between the sexes and across the agespan. J Nutr Health Aging. 2014;18(4):429–36. doi:.https://doi.org/10.1007/s12603-014-0001-y
  5. Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract. 2005;17(4):123–32. doi:.https://doi.org/10.1111/j.1041-2972.2005.0020.x
  6. Morin L, Laroche ML, Texier G, Johnell K. Prevalence of Potentially Inappropriate Medication Use in Older Adults Living in Nursing Homes: A Systematic Review. J Am Med Dir Assoc. 2016;17(9):862.e1–9. doi:.https://doi.org/10.1016/j.jamda.2016.06.011
  7. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370(9582):173–84. doi:.https://doi.org/10.1016/S0140-6736(07)61091-5
  8. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63(11):2227–46. doi:.https://doi.org/10.1111/jgs.13702
  9. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315(7115):1096–9. doi:.https://doi.org/10.1136/bmj.315.7115.1096
  10. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC ; UCLA Division of Geriatric Medicine. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med. 1991;151(9):1825–32. doi:.https://doi.org/10.1001/archinte.1991.00400090107019
  11. Storms H, Marquet K, Aertgeerts B, Claes N. Prevalence of inappropriate medication use in residential long-term care facilities for the elderly: A systematic review. Eur J Gen Pract. 2017;23(1):69–77. doi:.https://doi.org/10.1080/13814788.2017.1288211
  12. McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ. 1997;156(3):385–91.
  13. Laroche ML, Charmes JP, Merle L. Potentially inappropriate medications in the elderly: a French consensus panel list. Eur J Clin Pharmacol. 2007;63(8):725–31. doi:.https://doi.org/10.1007/s00228-007-0324-2
  14. Holt S, Schmiedl S, Thürmann P. PRISCUS-Liste potenziell inadäquater Medikation für ältere Menschen. Berlin: Bundesministerium für Bildung und Forschung BMBF; 2011. Available at: http://priscus.net/download/PRISCUS-Liste_PRISCUS-TP3_2011.pdf
  15. Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861–75. doi:.https://doi.org/10.1007/s00228-015-1860-9
  16. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol. 2010;69(5):543–52. doi:.https://doi.org/10.1111/j.1365-2125.2010.03628.x
  17. Wang KN, Bell JS, Chen EYH, Gilmartin-Thomas JFM, Ilomäki J. Medications and Prescribing Patterns as Factors Associated with Hospitalizations from Long-Term Care Facilities: A Systematic Review. Drugs Aging. 2018;35(5):423–57. doi:.https://doi.org/10.1007/s40266-018-0537-3
  18. Chiatti C, Bustacchini S, Furneri G, Mantovani L, Cristiani M, Misuraca C, et al. The economic burden of inappropriate drug prescribing, lack of adherence and compliance, adverse drug events in older people: a systematic review. Drug Saf. 2012;35(S1, Suppl 1):73–87. doi:.https://doi.org/10.1007/BF03319105
  19. Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370(9582):185–91. doi:.https://doi.org/10.1016/S0140-6736(07)61092-7
  20. Blozik E, Rapold R, von Overbeck J, Reich O. Polypharmacy and potentially inappropriate medication in the adult, community-dwelling population in Switzerland. Drugs Aging. 2013;30(7):561–8. doi:.https://doi.org/10.1007/s40266-013-0073-0
  21. Blozik E, Rapold R, Reich O. Prescription of potentially inappropriate medication in older persons in Switzerland: does the dispensing channel make a difference? Risk Manag Healthc Policy. 2015;8:73–80. doi:.https://doi.org/10.2147/RMHP.S78179
  22. Reich O, Rosemann T, Rapold R, Blozik E, Senn O. Potentially inappropriate medication use in older patients in Swiss managed care plans: prevalence, determinants and association with hospitalization. PLoS One. 2014;9(8):e105425. doi:.https://doi.org/10.1371/journal.pone.0105425
  23. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. doi:.https://doi.org/10.1186/s12877-017-0621-2
  24. Bundesamt für Statistik. Alterung der Bevölkerung. March 2017. Available at: https://www.bfs.admin.ch/bfs/de/home/statistiken/bevoelkerung/alterung.html.Last accessed on 16 Apr. 2019]).
  25. Bjerrum L, Rosholm JU, Hallas J, Kragstrup J. Methods for estimating the occurrence of polypharmacy by means of a prescription database. Eur J Clin Pharmacol. 1997;53(1):7–11. doi:.https://doi.org/10.1007/s002280050329
  26. Bundesamt für Statistik. Bevölkerung. April 2019. Available at: https://www.bfs.admin.ch/bfs/de/home/statistiken/bevoelkerung.html. Last accessed on 09 Apr. 2019.
  27. Hoffmann F, Schmiemann G, Dörks M. Untersuchungen zu Polypharmazie: Eine Frage der Definition und der verwendeten Daten [Assessment of polypharmacy: A question of definition and underlying data]. Z Evid Fortbild Qual Gesundhwes. 2016;113:27–35. German. doi:.https://doi.org/10.1016/j.zefq.2016.03.004
  28. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294(6):716–24. doi:.https://doi.org/10.1001/jama.294.6.716
  29. Farmer C, Fenu E, O’Flynn N, Guthrie B. Clinical assessment and management of multimorbidity: summary of NICE guidance. BMJ. 2016;354:i4843. doi:.https://doi.org/10.1136/bmj.i4843
  30. Cooper JA, Cadogan CA, Patterson SM, Kerse N, Bradley MC, Ryan C, et al. Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review. BMJ Open. 2015;5(12):e009235. doi:.https://doi.org/10.1136/bmjopen-2015-009235
  31. Onder G, Landi F, Liperoti R, Fialova D, Gambassi G, Bernabei R. Impact of inappropriate drug use among hospitalized older adults. Eur J Clin Pharmacol. 2005;61(5-6):453–9. doi:.https://doi.org/10.1007/s00228-005-0928-3
  32. Laroche ML, Charmes JP, Nouaille Y, Picard N, Merle L. Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol. 2007;63(2):177–86. doi:.https://doi.org/10.1111/j.1365-2125.2006.02831.x
  33. Pérez T, Moriarty F, Wallace E, McDowell R, Redmond P, Fahey T. Prevalence of potentially inappropriate prescribing in older people in primary care and its association with hospital admission: longitudinal study. BMJ. 2018;363:k4524. doi:.https://doi.org/10.1136/bmj.k4524
  34. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8. doi:.https://doi.org/10.1093/ageing/afu145
  35. Hovstadius B, Hovstadius K, Astrand B, Petersson G. Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008. BMC Clin Pharmacol. 2010;10(1):16. doi:.https://doi.org/10.1186/1472-6904-10-16
  36. Locca JF, Ruggli M, Buchmann M, Huguenin J, Bugnon O. Development of pharmaceutical care services in nursing homes: practice and research in a Swiss canton. Pharm World Sci. 2009;31(2):165–73. doi:.https://doi.org/10.1007/s11096-008-9273-9

Most read articles by the same author(s)

1 2 3 > >>